Post

CRISPR drug licensing deals secure $21bn in top three therapy areas over five years

Licensing agreements for innovator drugs utilising clustered regularly interspaced short palindromic repeats (CRISPR) technologies saw oncology, immunology, and central nervous system …

Xilio and Gilead partner up for IL-12 therapeutic development

Gilead Sciences and Xilio Therapeutics declared an exclusive license agreement for the development of a tumour-activated IL-12 program. Under the deal, …

Cheap drugs, inspections, and a future war in Europe – what’s driving drug shortages?

Drug shortages are worsening globally, leaving patients without access to essential medications, and healthcare providers struggling to find alternative treatments. …

Boundless Bio raises $100m as IPO market rouses

US-based Boundless Bio will offer 6,250,000 shares for $16 each as the oncology company hears the bell on the Nasdaq …

OSE Immunotherapeutics gets grant for anti-human SIRPA antibody for treating cancer

OSE Immunotherapeutics has been granted a patent for antibodies targeting human SIRPa, enhancing antigen presentation to T cells. The invention …